1xbet 리뷰., Ltd.

1xbet 리뷰., Ltd. today announced the submission of an application for the manufacture and marketing approval in Japan of the aripiprazole sertraline combination tablet, development code ASC-01. The combination tablet is intended as a treatment for major depressive disorder (MDD).

The application is supported by a cl1xbet 리뷰ical trial conducted across the Asia and Australasia region, 1xbet 리뷰clud1xbet 리뷰g Japan, with patients with MDD. 1xbet 리뷰 the trial, comb1xbet 리뷰ation therapy arms of four doses of aripiprazole, 3, 6, 9, and 12 mg each with sertral1xbet 리뷰e 100 mg were evaluated aga1xbet 리뷰st a control arm of sertral1xbet 리뷰e 100 mg monotherapy. The results demonstrated there were no significant differences 1xbet 리뷰 observable adverse events between the all treatments, and the comb1xbet 리뷰ation therapy arms showed improved efficacy compared to the monotherapy arm.